期刊文献+

伏立康唑引起视觉障碍临床分析 被引量:3

下载PDF
导出
摘要 目的:探讨静脉使用伏立康唑引起视觉障碍的表现及转归。方法300例合并侵袭性真菌感染患者静脉使用伏立康唑,其中有5例出现视觉障碍,对其临床资料、治疗及转归进行分析总结。结果5例患者使用伏立康唑1~3天后出现视觉障碍,5例出现视物模糊,3例出现色觉改变。5例患者视觉障碍均于停用伏立康唑后1~3天后好转,无复发。结论视觉障碍作为伏立康唑的不良反应之一,及早发现,处理及时,预后较佳。
出处 《海峡药学》 2016年第7期281-282,共2页 Strait Pharmaceutical Journal
  • 相关文献

参考文献7

  • 1Hideo K,Masayuki H,Kensuke O,et al.Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders:a prospective multicenter trial in Japan[J].Journal of Infection&Chemotherapy,2013,19(6):1126-1134.
  • 2王冬,曹江,江学维,白楠,汶柯,张勇,王瑾,王睿.伏立康唑致视觉障碍的文献计量学研究[J].药物不良反应杂志,2013,15(6):325-329. 被引量:24
  • 3李光辉,张婴元.三唑类抗真菌新药:伏立康唑[J].中国抗感染化疗杂志,2003,3(4):246-250. 被引量:25
  • 4Eiden C,Peyriere H M,Djezzar S,et al.Adverse effects of voriconazole:analysis of the French Pharmacovigilance Database[J].Annals of Pharmacotherapy,2007,41(5):755-763.
  • 5Kinoshita J,Iwata N,Ohba M,et al.Mechanism of voriconazole-induced transient visual disturbance:reversible dysfunction of retinal ON-bipolar cells in monkeys[J].Investigative Ophthalmology&Visual Science,2011,52(8):5058-5063.
  • 6Keith T,Nigel B,Konrad T,et al.Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities[J].Journal of Clinical Pharmacology,2006,46(2):235-243.
  • 7周义文,钱元恕.氟喹诺酮类药对人肝药酶活性的影响[J].中国新药与临床杂志,2003,22(9):523-528. 被引量:21

二级参考文献54

  • 1钱元恕,莫岚,兰雁飞,王其南.环丙沙星、氧氟沙星和诺氟沙星对大鼠肝微粒体混合功能氧化酶的作用[J].中国抗生素杂志,1994,19(6):459-463. 被引量:14
  • 2莫岚,钱元恕,王其南,许炜.培氟沙星对大鼠肝微粒体酶系的抑制作用[J].新药与临床,1995,14(1):15-17. 被引量:10
  • 3莫岚,钱元恕,王其南,兰雁飞.依诺沙星对大鼠肝药酶的抑制作用[J].中国抗生素杂志,1995,20(5):384-388. 被引量:13
  • 4[16]Lazarus HM, Blumer JL, Yanovich S, et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study[J]. J Clin Pharmacol, 2002,42:395-402
  • 5[17]Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis[J]. Clin Infect Dis, 2002,34:563-571
  • 6[18]Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J]. N Engl J Med, 2002 8,347:408-415
  • 7[19]Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients[J]. Clin Infect Dis, 2001, 33:1447-1454
  • 8[20]Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, et al. Voriconazole for the treatment of S. apiospermum and S. prolificans infection[abstract 305]. In: Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans). 2000
  • 9[21]Perfect JR, Lutsar I, Gonzalex-Ruiz A. Voriconazole for the treatment of resistant and rare fungal pathogens [abstract 303]. In: Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans). 2000
  • 10[22]Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole[J]. Br J Ophthalmol, 2000,84:932-933

共引文献61

同被引文献45

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部